- 1 Elevated prevalence and treatment of sleep disorders from 2011 to
- 2 2020; a nationwide population-based retrospective cohort study in
- 3 Korea
- 4 Eun Kyoung Ahn, Younghwa Baek, Ji-Eun Park, Siwoo Lee and Hee-
- 5 Jeong Jin<sup>\*</sup>
- 6 KM data division, Korea institute of oriental medicine, Republic of Korea
- 7 **\*Corresponding author:**
- 8 Full address: KM data division, Korea institute of oriental medicine, 1672, Yuseong-
- 9 daero, Yuseong-gu, Daejeon, 34054, Republic of Korea
- 10 e-mail address: hjjin@kiom.re.kr
- 11 telephone number: +82-42-868-9305
- 12 ORCID: Hee-Jeong Jin: https://orcid.org/0000-0002-4373-3410

13

## 14 Authors

- 15 1. Eun Kyoung Ahn, RN, Ph.D.
- 16 : ekahn@kiom.re.kr
- 17 KM data division, Korea institute of oriental medicine, Daejeon, Republic of Korea.
- 18 https://orcid.org/0000-0003-1784-793X
- 19 2. Younghwa Baek, RN, Ph.D.
- 20 : aori79@kiom.re.kr
- 21 KM data division, Korea institute of oriental medicine, Daejeon, Republic of Korea.
- 22 https://orcid.org/0000-0002-1827-1701
- 23 3. Ji-Eun Park, RN, Ph.D.
- 24 : jepark@kiom.re.kr
- 25 KM data division, Korea institute of oriental medicine, Daejeon, Republic of Korea.
- 26 https://orcid.org/0000-0002-2932-5373

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 27 4. Siwoo Lee, KMD
- 28 : bfree@kiom.re.kr
- 29 KM data division, Korea institute of oriental medicine, Daejeon, Republic of Korea.
- 30 https://orcid.org/0000-0003-2658-8175

# 31 Abstract

32	Objectives: This study used National Health Insurance claims data from Korea to report
33	the prevalence of sleep disorders and treatment status, including traditional Korean
34	medicine, in the last ten years.
35	Methods: This is a retrospective cohort study in Korea. All diagnosis and prescription
36	data, including herbal medicine claims, from the Health Insurance Review and
37	Assessment Service from 2011 to 2020 were reviewed. Prevalence estimation, direct
38	medical expenses, and prescribed amounts for sleep disorders were recorded.
39	<i>Results:</i> The prevalence of sleep disorders increased from 3,867,975 (7.62%) in 2011 to
40	7,446,846 (14.41%) in 2020, nearly doubling over 10 years. Insomnia was observed in
41	91.44% (n=9,011,692) of the patients. The mean number of hospital visits per patient
42	for sleep disorders was 11.5 (±26.62). Benzodiazepines are the most commonly
43	prescribed medications for sleep disorders, and gamma-isoyosan is the most frequently
44	prescribed herbal medicine.
45	Conclusions: Sleep disorders are continuously increasing, as is the use of medical
46	services – personal and social medical expenses are also increasing accordingly. Sleep
47	disorders should be recognized as a significant health problem that needs to be actively
48	addressed to improve quality of life.
49	<b>Keywords:</b> sleep disorders; claims data; prevalence; benzodiazepine; herbal
50	medicine
51	
52	
53	
54	
55	

56	Streng	ths and limitations of this study
57	•	This is a nationwide health insurance claims data for prevalence and the status
58		of treatment on sleep disorders for ten years.
59	•	This study will be meaningful because we have confirmed the current address
60		of the prevalence and treatment of sleep disorders in the last 10 years.
61	•	The data source has the limitation of being able to confirm only the items
62		subject to health insurance benefits and review.
63	•	The results of tests for the diagnosis of sleep disorders were not confirmed.
64		
65		
66	Word	count: 2,844 words

### 67 INTRODUCTION

68 Sleep disorders are highly related to chronic pain, cardiovascular disease, dementia, metabolic syndrome, and digestive dysfunction<sup>1-4</sup>, and reportedly increase the death 69 70 risk, deteriorates quality of life and overall health condition resulting to patient's 71 economic burden<sup>5,6</sup>. Short-term insomnia occurs in 30–50% of the population<sup>7</sup>. The prevalence of sleep disorders in the United States was 20–41.7% in 2011<sup>8</sup>, and from 72 2013–2016, the prevalence increased by approximately  $40\%^9$ . The prevalence of 73 insomnia is at least 6% in developed countries<sup>10</sup>, 10% in Norway and England<sup>11,12</sup>, 5.7% 74 in Germany<sup>13</sup>, and 19% in France<sup>14</sup>. In the cases of Asia, Japan recorded 13.5% of 75 insomnia cases in 2016<sup>15</sup>. In Korea, 17–23% of cases were recorded as insomnia, and 76 77 another study reported 5% of insomnia cases meeting the DSM-IV diagnostic criteria<sup>16,17</sup>. Moreover, in situations of heightened personal and social stress, such as the 78 79 COVID-19 pandemic, the worldwide prevalence of sleep disorders has surged to approximately 40%<sup>18</sup>. Sleep disorders are becoming common in our society; it is 80 81 considered that the scale of physical, mental, economic, and social damage is very 82 likely to increase in the long term. Sleep disorders may appear and disappear temporarily but often persist chronically. Reports on the nature of insomnia show that 83 84 approximately 46% of patients have experienced the symptoms continuously for 3 years<sup>19</sup>, while other studies have shown that approximately 45% of patients 85 continuously experience insomnia after its  $onset^{20,21}$ . 86 87 There are both nonpharmacological and pharmacological treatment strategies for sleep

disorders. Typically, pharmacological therapy is provided if there is no response to

89 cognitive behavioural therapy (CBT) or if treatment is not feasible. Medication

90 prescribed for sleep initiation or maintenance disorders is distinguished<sup>22-24</sup>. The

91 European Sleep Research Society (ESRS) treatment guidelines for sleep disorder 92 treatment recommend that benzodiazepines and z-drugs should not be used for long-93 term treatment<sup>23</sup>. Moreover, the American College of Physicians (ACT) treatment 94 guidelines recommend using these drugs for a short period (4–5 weeks) only, as 95 approved by the US Food and Drug Administration (FDA)<sup>22</sup>. Chronic use of sleeping 96 pills increases the risk of side effects such as daytime sleepiness, ataxia, dizziness, 97 cognitive decline, increased aggressive behavior, delirium, worsening of apnea, and 98 increased risk of dementia<sup>25-28</sup>. In Korea and China, patients may choose sleep disorder 99 treatments such as acupuncture or herbal medicine as alternatives to initial treatment or 100 long-term medication. According to the Clinical Practice Guideline (CPG) of Korean 101 medicine for insomnia disorders, insomnia treatment is divided into herbal medicine, 102 acupuncture, and non-acupuncture herbal medicine treatment<sup>29</sup>, depending on the 103 symptoms, acupuncture, and herbal medicine alone or in combination treatment takes 104 place.

Sleep disorders are gradually increasing in prevalence and they are a health issue requiring long-term approaches. However, no precise treatment has been developed for sleep disorders. Treatment strategies, such as cognitive therapy, acupuncture, and medication, including herbal medicine, are used in clinical practice to treat sleep disorders. Sleep disorder is not a direct condition that causes death in humans; however, it is a condition that affects the quality of life, disease prognosis, and mortality. Hence, it is crucial to grasp the current status of its prevalence and common treatment.

In this study, based on data claims from the Korean National Health Insurance Service,
sleep disorders over the past 10 years (2011-2020) included medical and institutional
information on both Western and Korean medicine, including covered medications,

- sleep tests, and treatment prescriptions. This study determined the prevalence and
- 116 overall treatment characteristics for sleep disorders in Korea.

### 117 METHODS

#### 118 **Data source and study population**

119 In the current retrospective cohort study, a set of research data (No. M20210819448)

120 was provided by the Healthcare Big Data Hub of the Health Insurance Review and

121 Assessment Service (HIRA) of Korea. The research data were pseudonymized, and

122 provision was determined by the HIRA's Public Data Provision Deliberation

- 123 Committee. The study's protocol was also exempted from ethical review by the
- 124 Institutional Review Board of the Korea Institute of Oriental Medicine (IRB No. I-

125 2107/006-001).

126 The data included all patients diagnosed with sleep disorders as a primary or secondary

127 diagnosis between January 1, 2011, and December 31, 2020. Medical records

128 containing information on sleep disorder diagnoses were extracted based on the

129 diagnosis code registered by the treating doctor. Individuals diagnosed with sleep

130 disorders at least once during the observation period and prescribed medication were

131 enrolled in this study. Subjects of all ages were included; however, veterans were

132 excluded from the study.

### 133 Sleep disorders

- 134 The Korean Standard Classification of Diseases version 7 (KCD-7) was used to identify
- 135 subjects with sleep disorders. The KCD-7 code is based on the International
- 136 Classification of Diseases version 10 (ICD-10) code system and reflects the unique

137 disease characteristics of Korea. The subdivision classification for frequent diseases, 138 reorganization of the Korean medicine classification, and diagnostic codes for rare 139 diseases are also reflected. Sleep disorders were classified according to the criteria of 140 the third edition of the International Classification of Sleep Disorders  $(ICSD-3)^{24}$ ; 141 insomnia, sleep-related breathing disorders, sleep-related movement disorders, circadian 142 rhythm sleep-wake disorders, central disorders of hypersomnolence, parasomnia, and 143 other unspecified sleep disorders. The sleep disorder classification, KCD-7, and detailed 144 diagnoses are provided in Supplementary table 1.

### 145 Medications for sleep disorders

146 Drugs approved by the Korea Food and Drug Administration (KFDA) for insomnia are

147 classified into benzodiazepines, non-benzodiazepines, antidepressants, antihistamines,

148 and antipsychotics. Korea has a dual medical service system; therefore, herbal medicine

149 prescriptions are available. A list of the licensed drugs for the indication of sleep

150 disorders, including herbal medicines, is provided in Supplementary table 2. In the

151 present study, all 56 types of herbal medicines reimbursed (Supplementary table 3) that

152 are subject to review by HIRA were reviewed. Herbal medicines for sleep disorder

153 indications included Gamisoyo-san, Hwanglyeonhaedok-tang, Galgeunhaegui-tang,

154 Dangguiyukhwang-tang, and Sosiho-tang.

#### 155 Data preprocessing and statistical analysis

156 The data was analyzed by accessing a remote analysis system provided by the

157 Healthcare Big Data Hub. Remote access to a virtualized Personal Computer (PC) is

158 only possible from PCs approved by researchers and authorized in advance. In order to

159 calculate the prevalence of sleep disorders by year, individual subjects diagnosed with

160 sleep disorders and prescribed medications were counted. The total population was 161 calculated based on the population by the end of December of each year, as announced 162 by the Ministry of Public Administration and Security's Annual Statistical Yearbook 163 Population<sup>25</sup>. It is calculated based on different criteria according to the nature of each 164 variable. Prevalence cases were based on the number of individuals affected with sleep 165 disorders, while the number of cases for medical use was based on the medical use 166 statement. Medication and treatments, on the other hand, were based on individual 167 prescriptions. Age, number of cases of medical use per person, and medical expenses 168 were reported as the mean and standard deviation. The use of Korean and Western 169 medical services, the distinction between hospitalization and outpatient treatment, type 170 of sleep disorder, sex, and medications or test prescriptions were presented as numbers 171 and percentages. Medical expenses were expressed in South Korean Won (KRW). 172 Statistical differences between groups were reported based on a significance level of p 173 <0.05. The Statistical Analysis System (SAS) Enterprise Guide version 9.4.2 (SAS) 174 institute Inc., SAS Campus Drive Cary, NC, USA), installed on a virtualized PC, was 175 used for pre-processing and statistical analysis of the research data.

#### 176 **RESULTS**

### 177 General information

178 A total of 7,467,730 subjects used medical care due to sleep disorder diagnosis, of

179 which 59.62% (n=4,452,628) were female patients, from 2011–2020. The mean age for

- 180 the entire population was  $53.47 \pm 17.95$  years old, while the mean age for men and
- 181 women was  $52.31 \pm 18.18$  and  $54.26 \pm 17.74$ , respectively. The mean age of women was
- 182 higher compared to male. When age was divided into 10-year-old units, the number of
- 183 patients with sleep disorders increased with age, and the highest number of patients was

seen in the age group between 50 and 60 years, then gradually decreasing (Table 1). For
the distribution by type of sleep disorder according to the ICSD-3, 'insomnia' was
diagnosed in 91.44% (n= 9,011,692 cases); hence, the most common type of sleep
disorder that was recorded in visiting medical institutions. 'Other unspecified sleep
disorders' accounted for 6.89% (n=679,400), and the rest sleep disorders accounted for
less than 1% of total (Figure 1).

### 190 Annual prevalence of sleep disorders and use of medical services

191 The annual prevalence of sleep disorders in patients aged >10 years increased from

192 3,867,975 (7.62%) in 2011 to 7,446,846 (14.41%) in 2020, nearly doubling in 10 years.

193 The number of male patients increased from 1,477,614 (5.82%) to 2,987,309 (11.56%),

and the number of female patients increased from 2,390,361 (9.44%) to 4,459,537

195 (17.27%); with rates increase being similar (Figure 2, Supplementary table 4). The

196 mean number of visits to the hospital for sleep disorder diagnosis for the past 10 years

197 was 11.55±26.62, and women visited the hospital (11.96±27.43) more often than men

198  $(10.94 \pm 25.37)$ . The total hospital visits also increased from 5, 932, 505 in 2011 to

199 11,111,518 by 2020. Hospital visits increased from 37.1% to 39.1% in men and

200 decreased from 62.9% to 60.9% among women. There has been an increase in the total

201 number of patients that are women and the number of hospital visits for men (Figure 3).

202 Of the total hospital visits for sleep disorders, Korean medical treatment accounts for

203 approximately 9.65% (N =8,323,747). A total of 11.39% (n=6,066,211) of women

visited a Korean medical institute, which was higher than that of men (6.84%,

n=2,257,536). The mean number of hospital visits per patient was  $11.7\pm$ SD 27.4 for

women and 10.9±25.4 for men. The mean cost of total medical expenses per visit was

207 71,931 KRW, and the mean cost per patient was 830,707 KRW (Table 2).

#### 208 Medication prescriptions and others

209	Over the past decade, medications covered by the National Health Insurance for Sleep
210	Disorders in Korea included 51,095,781 (47.7%) prescriptions for benzodiazepines,
211	31,325,590 (29.2%) prescriptions for non-benzodiazepines, and 17,457,246 (16.3%)
212	prescriptions for antidepressants. As for the National Health Insurance, the herbal
213	medicines prescribed for sleep disorders were 100,065 cases of Gamisoyo-san, 23,841
214	cases of Hwanglyeonhaedok-tang, and 11,490 cases of Sosiho-tang (Figure 4).
215	Excluding herbal medicines, acupuncture was the most frequently prescribed treatment
216	(13,727,099 cases), followed by moxibustion, hot/cold physical therapy, electronic
217	needle stimulation, and cupping (Supplementary Figure 1).

218 **DISCUSSION** 

219 The prevalence of sleep disorders in Korea has nearly doubled over the past 10 years, 220 from 9.4% in 2011 to 17.3% in 2020. Similarly, sleep disorder prevalence in countries 221 like the United States, Norway, England, Germany, and Japan has also shown an overall increasing trend<sup>7-9,11-13,15,17</sup>. Several possible explanations exist for this recent increase 222 223 in the prevalence of sleep disorders. First, it can be assumed that primary or secondary 224 sleep disorders will increase in absolute numbers, and secondary sleep disorders, such 225 as insomnia, are caused by the use of drugs and substances or by medical or psychiatric diseases and are known to account for more than 70% of all insomnia<sup>31</sup>. The prevalence 226 227 of secondary sleep disorders also increases with the prevalence of cancer, Parkinson's 228 disease, and degenerative cerebrovascular diseases such as dementia and obesity, which are well-known causes of sleep disorders<sup>32-34</sup>. Furthermore, since 2020, the number of 229 230 people complaining about sleep disorders has increased worldwide, which could be the aftermath of the COVID-19 pandemic<sup>35</sup>. The second reason may be the behavioural 231

232 change in seeking medical services to solve the problem, as patients' perceptions of 233 sleep disorders change. Previously, sleep disorders, such as insomnia, were regarded as 234 secondary symptoms resulting from diseases rather than a single disease. However, as ICSD-2 was revised to ICSD-3; hence, insomnia disorder was suggested<sup>24</sup>. Accordingly. 235 236 there has been an apparent change in insomnia recognition as a disease requiring 237 treatment, such as paying attention to classification according to Objective Sleep 238 Duration (OSD) in clinical practice and applying it to treating insomnia cases<sup>36</sup>. In 239 2017, the American Academy of Sleep Medicine and European Academy of Sleep 240 Medicine published guidelines for insomnia treatment that preferentially recommend cognitive behavioral therapy (CBT-I)<sup>23,37</sup>. 241 Hospital visits owing to sleep disorders were more frequent among women than 242 243 among men. Previous studies have shown sex differences in the prevalence and types of 244 sleep disorders. A meta-analysis of sex differences in the prevalence of insomnia reported a significantly higher prevalence in women<sup>38</sup>. The high prevalence of sleep 245 246 disorders in women, including insomnia, is multifactorial. It may be because women are 247 more likely to experience physical problems such as osteoporosis, fractures, and joint 248 diseases, which affect sleep quality, and they have a higher risk of developing 249 psychiatric problems such as depression and anxiety, resulting to increase insomnia 250 risk<sup>39</sup>. According to the results of this study, insomnia accounts for more than 90% of 251 all sleep disorders. Hence, the above factors can explain women's higher prevalence of 252 sleep disorders. In contrast, in the case of obstructive sleep apnea (OSA), the proportion 253 of all sleep disorders is low, so it does not have a significant effect on the overall 254 prevalence; however, it is well-known that it has a higher prevalence in men<sup>40,41</sup>. 255 The current study confirmed that the average age for sleep disorder diagnosis in Korea 256 is 53.5 years old and that the number of patients with sleep disorders tends to increase.

257 There are many elderly patients with sleep disorders because sleep quality decreases 258 with age owing to the apparent evolutionary biological relationship between aging and 259 sleep. Many sleep-related studies have reported that subjective and objective sleep quality deteriorates with  $age^{42,43}$ . Moreover, according to a study comparing the sleep of 260 261 older and younger adults, older adults spend less time in slow-wave sleep, resulting in a reduced percentage of deep sleep<sup>44</sup>. As individuals age, sleep becomes more 262 263 fragmented, leading to changes in sleep stages and more frequent awakenings<sup>45</sup>. Sleep 264 homeostasis decreases with age<sup>46</sup>. Furthermore, the prevalence of diseases that cause 265 sleep disorders, such as metabolic disorders, cardiovascular diseases, neurodegenerative diseases, and cancer, increases with age<sup>47-51</sup>. 266 267 Insomnia is the most common sleep disorder among the sleep disorder types, 268 according to ICSD-3, and approximately 17.5% of Koreans visit hospitals for insomnia. 269 Insomnia is "a persistent difficulty with sleep initiation, duration, consolidation, or 270 quality that occurs despite adequate opportunity and circumstances for sleep and results 271 in some form of daytime impairment"<sup>52</sup>. According to another study (2005 - 2013) that 272 reported the prevalence and incidence of insomnia in Korea, 5.78% of adults aged 20 273 years or older had insomnia<sup>53</sup>. Additionally, approximately 17% of the total subjects in 274 a study reported insomnia in 2002, and 22.8% of subjects in a 2009 study reported 275 insomnia<sup>16,17</sup>. Insomnia is Korea's most common sleep disorder, and its incidence 276 steadily increases. 277 Over the past 10 years, the mean number of hospital visits due to sleep disorders in 278 Korea was 11.5, and the mean total medical expense for one patient during the 279 observation period was 830,707 KRW (629.13 USD). The insomnia related examination cost \$3,508,635 which was about half of total insomnia-related medical expenses<sup>54</sup>. 280 281 Australia reported total direct health expenditures related to inadequate sleep of

approximately 1.24 billion AUD from 2016–2017<sup>55</sup>. In the United States, the direct 282 medical cost due to insomnia in 1995 was estimated at approximately \$13.9 billon<sup>56</sup>. 283 284 and in a review paper on the health economics of insomnia treatment published in 2016, it exceeds \$100 billion per year for insomnia treatment<sup>57</sup>. In the United States, 285 286 direct/indirect social costs due to insomnia increased approximately 10 times over 287 nearly 20 years, most of which contributed to indirect costs such as reduced work 288 performance, increased use of medical care, and increased risk of accidents<sup>57</sup>. The social 289 cost to be paid due to sleep disorders is increasing at a non-negligible rate over time, 290 and improving sleep quality seems to be a social task to be solved. 291 Among the prescription drugs for sleep disorders, benzodiazepines accounted 292 for 47.8%, and non-benzodiazepines accounted for 29.3%. According to the Korean Neuropsychiatric Association guidelines for insomnia treatment, CBT is recommended 293 first<sup>58</sup>. Sleeping pills are an effective and easy method for treating insomnia, but they 294 295 carry the risk of dependence and abuse. The KFDA and treatment guidelines 296 recommend shortening drug treatment for unremedied insomnia, mostly within four 297 weeks. In Korea, approximately 10% of patients were prescribed herbal medicine for 298 treating sleep disorders. In practice, medicines in Western medicine and herbal 299 medicines in Korean medicine are prescribed separately or together to treat sleep 300 disorders. However, studies on the effects or side effects of combined prescribed and 301 herbal medicines in patients with sleep disorders are lacking. 302 The data source of the present study has the advantage of being able to estimate 303 the medical use behaviour of the entire population but also has the limitation of being 304 able to confirm only the items subject to health insurance benefits and review. 305 Information on uncovered herbal medicines or decoctions not subject to health 306 insurance review could not be counted for the herbal medicine. Additionally, the results

307	of tests for the	diagnosis of slee	n disorders were not	confirmed. Nevertheless, w	ve
507					* 0

- 308 believe it will be meaningful because we have confirmed the current address of the
- 309 prevalence and treatment of sleep disorders in the last 10 years.
- 310 In conclusion, sleep disorders are continuously increasing with more individuals
- 311 seeking medical intervention resulting in increased personal and social medical
- 312 expenses. Sleep disorders should be recognized as a significant health problem that
- 313 needs to be actively addressed to improve quality of life.
- 314

#### 315 Contributors

- 316 Conceptualization was done by EKA, YB, and HJJ. Methodology was done by EKA.
- 317 The original draft was written by EKA and HJJ. Review and editing were done by YB,
- 318 JP, SL and HJJ. Funding was acquired by JP and SL. Supervision was done by HJJ.
- 319 Acknowledgements
- 320 We would like to thank Editage (www.editage.co.kr) for English language editing.
- **321 Declaration of Interest Statement**
- 322 The authors declare that they have no conflicts of interest regarding the publication of
- this paper.

### 324 Funding

- 325 This study was supported by the grant from Korea Institute of Oriental Medicine
- 326 (KSN2023120, KSN20234113).
- 327 **Disclosure statement**
- 328 The funding source played no role in the interpretation of the study results or the
- 329 decision to submit these results for publication.
- 330 Data availability statement

- 331 The data that support the findings of this study are available from the Healthcare Big
- 332 Data Hub of the HIRA. However, restrictions apply with regard to availability as they
- 333 were used under license for research in the current study; therefore, these data are not
- 334 publicly available.
- 335

345

346

347

348

359

360

#### 336 **REFERENCES**

- Cappuccio, Francesco P.; MILLER, Michelle A. Sleep and cardio-metabolic
   disease. *Current cardiology reports* 2017;19: 1-9.
- 339
  340
  340
  341
  2. Khanijow, V., Prakash, P., Emsellem, H. A., Borum, M. L., & Doman, D. B. Sleep Dysfunction and Gastrointestinal Diseases. *Gastroenterol Hepatol* 2015;11(12): 817–25.
- 342
  3. Mathias, J. L., Cant, M. L., & Burke, A. L. J. Sleep disturbances and sleep
  343 disorders in adults living with chronic pain: a meta-analysis. *Sleep Med*344 2018;52: 198–210. https://doi.org/10.1016/j.sleep.2018.05.023
  - Shi, L., Chen, S. J., Ma, M. Y., Bao, Y. P., Han, Y., Wang, Y. M., Shi, J., Vitiello, M. V., & Lu, L. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. *Sleep Med Rev* 2018;40: 4–16. https://doi.org/10.1016/j.smrv.2017.06.010
- 349
  5. Oh, T. K., & Song, I. Five-year mortality trends associated with sleep disorders
  350 in South Korea: a population-based cohort study. *Sleep Biol Rhythms*351 2021;19(3): 305-12.
- Skaer, T. L., & Sclar, D. A. Economic implications of sleep disorders.
   *Pharmacoecon Open* 2010;28(11): 1015–23. https://doi.org/10.2165/11537390-000000000-00000
- F. Ellis, J. G., Perlis, M. L., Neale, L. F., Espie, C. A., & Bastien, C. H. The natural history of insomnia: focus on prevalence and incidence of acute insomnia. *J Psychiatr Res* 2012;46(10): 1278–85.
  https://doi.org/10.1016/j.jpsychires.2012.07.001
  - 8. Ohayon, M. M. Epidemiological Overview of sleep Disorders in the General Population. *Sleep Med Res* 2011;1(1): 1-9.
- 361
  9. Acquavella, J., Mehra, R., Bron, M., Suomi, J. M., & Hess, G. P. Prevalence of arcolepsy and other sleep disorders and frequency of diagnostic tests from 2013-2016 in insured patients actively seeking care. *J Clin Sleep Med* 2020;16(8): 1255–63. https://doi.org/10.5664/jcsm.8482
- 365 10. Ohayon M. M. Epidemiology of insomnia: what we know and what we still
  a66 need to learn. *Sleep Med Rev* 2002;6(2): 97–111.
  bttps://doi.org/10.1053/smrv.2002.0186
- 11. Calem, M., Bisla, J., Begum, A., Dewey, M., Bebbington, P. E., Brugha, T.,
  Cooper, C., Jenkins, R., Lindesay, J., McManus, S., Meltzer, H., Spiers, N.,
  Weich, S., & Stewart, R. Increased prevalence of insomnia and changes in
  hypnotics use in England over 15 years: analysis of the 1993, 2000, and 2007
  National Psychiatric Morbidity Surveys. *Sleep* 2012;35(3): 377–84.
  https://doi.org/10.5665/sleep.1700

374 375	12.	Pallesen, S., Sivertsen, B., Nordhus, I. H., & Bjorvatn, B. A 10-year trend of insomnia prevalence in the adult Norwegian population. <i>Sleep Med</i> 2014;15(2):
376		173–9. https://doi.org/10.1016/j.sleep.2013.10.009
377	13.	Schlack, R., Hapke, U., Maske, U., Busch, M., & Cohrs, S. [Frequency and
378		distribution of sleep problems and insomnia in the adult population in
379		Germany: results of the German Health Interview and Examination Survey for
380		Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung
381		Gesundheitsschutz 2013;56(5-6): 740-8. https://doi.org/10.1007/s00103-013-
382		1689-2
383	14.	Leger, D., Guilleminault, C., Dreyfus, J. P., Delahaye, C., & Paillard, M.
384		Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res
385		2000;9(1): 35–42. https://doi.org/10.1046/j.1365-2869.2000.00178.x
386	15.	Itani, O., Kaneita, Y., Munezawa, T., Mishima, K., Jike, M., Nakagome, S.,
387		Tokiya, M., & Ohida, T. Nationwide epidemiological study of insomnia in
388		Japan. Sleep Med 2016;25: 130–8. https://doi.org/10.1016/j.sleep.2016.05.013
389	16.	Ohayon, M. M., & Hong, S. C. Prevalence of insomnia and associated factors
390		in South Korea. J Psychosom Res 2002;53(1): 593-600.
391		https://doi.org/10.1016/s0022-3999(02)00449-x
392	17.	Cho, Y. W., Shin, W. C., Yun, C. H., Hong, S. B., Kim, J., & Earley, C. J.
393		Epidemiology of insomnia in korean adults: prevalence and associated factors.
394		J Clin Neurol 2009;5(1): 20–3. https://doi.org/10.3988/jcn.2009.5.1.20
395	18.	Jahrami, H., BaHammam, A. S., Bragazzi, N. L., Saif, Z., Faris, M., & Vitiello,
396		M. V. Sleep problems during the COVID-19 pandemic by population: a
397		systematic review and meta-analysis. J Clin Sleep Med 2021;17(2): 299–313.
398		https://doi.org/10.5664/jcsm.8930
399	19.	Morin, C. M., Bélanger, L., LeBlanc, M., Ivers, H., Savard, J., Espie, C. A.,
400		Mérette, C., Baillargeon, L., & Grégoire, J. P. The natural history of insomnia:
401		a population-based 3-year longitudinal study. Arch Intern Med 2009;169(5):
402		447–453. https://doi.org/10.1001/archinternmed.2008.610
403	20.	Drake, C. L., Roehrs, T., & Roth, T. Insomnia causes, consequences, and
404		therapeutics: an overview. <i>Depress Anxiety</i> 2003;18(4): 163–76.
405		https://doi.org/10.1002/da.10151
406	21.	Janson, C., Lindberg, E., Gislason, T., Elmasry, A., & Boman, G. Insomnia in
407		men-a 10-year prospective population-based study. <i>Sleep</i> 2001;24(4): 425–30.
408		https://doi.org/10.1093/sleep/24.4.425
409	22.	Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., &
410		Clinical Guidelines Committee of the American College of Physicians.
411		Management of Chronic Insomnia Disorder in Adults: A Clinical Practice
412		Guideline From the American College of Physicians. Ann Intern Med
413		2016;165(2): 125-33. https://doi.org/10.7326/M15-2175
414	23.	Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis,
415		J. G., Espie, C. A., Garcia-Borreguero, D., Gjerstad, M., Gonçalves, M.,
416		Hertenstein, E., Jansson-Fröjmark, M., Jennum, P. J., Leger, D., Nissen, C.,
417		Parrino, L., Paunio, T., Pevernagie, D., Verbraecken, J., Weeß, H. G.,
418		Spiegelhalder, K. European guideline for the diagnosis and treatment of
419		insomnia. J Sleep Res 2017;26(6): 675–700. https://doi.org/10.1111/jsr.12594
420	24.	Sateia M. J. International classification of sleep disorders-third edition:
421		highlights and modifications. Chest 2014;146(5): 1387-94.
422		https://doi.org/10.1378/chest.14-0970

423	25.	Population Data of Statistical Yearbooks. [Retrieved 23 Aug 2022 from
424	•	https://jumin.mois.go.kr]
425	26.	Billioti de Gage, S., Pariente, A., & Bégaud, B. Is there really a link between
426		benzodiazepine use and the risk of dementia? Expert Opin Drug Saf
427		2015;14(5): 733–47. https://doi.org/10.1517/14740338.2015.1014796
428	27.	French, D. D., Spehar, A. M., Campbell, R. R., Palacios, P., Coakley, R. W.,
429		Coblio, N., Angaran, D. M. Outpatient Benzodiazepine Prescribing, Adverse
430		Events, and Costs. In K. Henriksen, J. B. Battles, E. S. Marks, & D. I. Lewin
431		(Eds.), Advances in Patient Safety: From Research to Implementation (Volume
432		1: Research Findings). Rockville (MD): Agency for Healthcare Research and
433		Quality (US); 2005 Feb. https://www.ncbi.nlm.nih.gov/pubmed/21249782
434	28.	Gray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A.,
435		Crane, P. K., & Larson, E. B. Benzodiazepine use and risk of incident dementia
436		or cognitive decline: prospective population-based study. BMJ 2016;352: i90.
437		https://doi.org/10.1136/bmj.i90
438	29.	Sadock BJ, S. V., Ruiz P. Kaplan & Sadock's Synopsis of Psychiatry. Wolters
439		<i>Kluwer</i> 2015.
440	30.	Neuropsychiatry, T. S. o. K. M. Insomnia Disorder: Clinical Practice Guideline
441		of Korean Medicine (2.0 ed.) National Institute for Korean Medicine
442		Development 2021.
443	31.	Buysse, D. J., Reynolds, C. F., 3rd, Kupfer, D. J., Thorpy, M. J., Bixler, E.,
444		Manfredi, R., Kales, A., Vgontzas, A., Stepanski, E., & Roth, T. Clinical
445		diagnoses in 216 insomnia patients using the International Classification of
446		Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: a report from the
447		APA/NIMH DSM-IV Field Trial. Sleep 1994;17(7): 630–7.
448		https://doi.org/10.1093/sleep/17.7.630
449	32.	Mogavero, M. P., DelRosso, L. M., Fanfulla, F., Bruni, O., & Ferri, R. Sleep
450		disorders and cancer: State of the art and future perspectives. <i>Sleep Med Rev</i>
451		2021;56: 101409. https://doi.org/10.1016/j.smrv.2020.101409
452	33.	Muscogiuri, G., Barrea, L., Annunziata, G., Di Somma, C., Laudisio, D., Colao,
453		A., & Savastano, S. Obesity and sleep disturbance: the chicken or the egg? <i>Crit</i>
454		<i>Rev Food Sci Nutr</i> 2019;59(13): 2158–65.
455		https://doi.org/10.1080/10408398.2018.1506979
456	34.	Shen, Y., & Liu, C. F. Sleep Disorders in Parkinson's Disease: Present Status
457		and Future Prospects. Chin Med J 2018;131(8): 883–5.
458		https://doi.org/10.4103/0366-6999.229903
459	35.	Marvaldi, M., Mallet, J., Dubertret, C., Moro, M. R., & Guessoum, S. B.
460		Anxiety, depression, trauma-related, and sleep disorders among healthcare
461		workers during the COVID-19 pandemic: A systematic review and meta-
462		analysis. Neurosci Biobehav Rev 2021;126: 252–64.
463		https://doi.org/10.1016/j.neubiorev.2021.03.024
464	36.	Vgontzas, A. N., Fernandez-Mendoza, J., Liao, D., & Bixler, E. O. Insomnia
465		with objective short sleep duration: the most biologically severe phenotype of
466		the disorder. <i>Sleep Med Rev</i> 2013;17(4): 241–54.
467		https://doi.org/10.1016/j.smrv.2012.09.005
468	37.	Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L.
469		Clinical Practice Guideline for the Pharmacologic Treatment of Chronic
470		Insomnia in Adults: An American Academy of Sleep Medicine Clinical
471		Practice Guideline. J Clin Sleep Med 2017;13(2): 307–49.
472		https://doi.org/10.5664/jcsm.6470

473	38.	Zeng, L. N., Zong, Q. Q., Yang, Y., Zhang, L., Xiang, Y. F., Ng, C. H., Chen,
474		L. G., & Xiang, Y. T. Gender Difference in the Prevalence of Insomnia: A
475		Meta-Analysis of Observational Studies. <i>Front Psychiatry</i> 2020;11: 577429.
476		https://doi.org/10.3389/fpsyt.2020.577429
477	39.	Murtagh, K. N., & Hubert, H. B. Gender differences in physical disability
478	07.	among an elderly cohort. Am J Public Health 2004;94(8): 1406–11.
479		https://doi.org/10.2105/ajph.94.8.1406
480	40	Krishnan, V., & Collop, N. A. Gender differences in sleep disorders. <i>Curr Opin</i>
481	40.	Pulm Med 2006;12(6): 383–9.
482		https://doi.org/10.1097/01.mcp.0000245705.69440.6a
482	11	Theorell-Haglöw, J., Miller, C. B., Bartlett, D. J., Yee, B. J., Openshaw, H. D.,
483	41.	•
		& Grunstein, R. R. Gender differences in obstructive sleep apnoea, insomnia
485		and restless legs syndrome in adults - What do we know? A clinical update.
486	40	<i>Sleep Med Rev</i> 2018;38: 28–38. https://doi.org/10.1016/j.smrv.2017.03.003
487	42.	Roepke, S. K., & Ancoli-Israel, S. Sleep disorders in the elderly. <i>Indian J Med</i>
488		<i>Res</i> 2010;131: 302–10.
489	43.	Tatineny, P., Shafi, F., Gohar, A., & Bhat, A. Sleep in the Elderly. <i>Mo Med</i>
490		2020;117(5): 490–5.
491	44.	Ohayon, M. M., Carskadon, M. A., Guilleminault, C., & Vitiello, M. V. Meta-
492		analysis of quantitative sleep parameters from childhood to old age in healthy
493		individuals: developing normative sleep values across the human lifespan.
494		Sleep 2004;27(7): 1255–73. https://doi.org/10.1093/sleep/27.7.1255
495	45.	Van Cauter, E., Leproult, R., & Plat, L. Age-related changes in slow wave sleep
496		and REM sleep and relationship with growth hormone and cortisol levels in
497		healthy men. JAMA 2000;284(7): 861–8.
498		https://doi.org/10.1001/jama.284.7.861
499	46.	Dijk, D. J., Duffy, J. F., Riel, E., Shanahan, T. L., & Czeisler, C. A. Ageing and
500		the circadian and homeostatic regulation of human sleep during forced
501		desynchrony of rest, melatonin and temperature rhythms. J Physiol 1999;516
502		(Pt 2): 611–27. https://doi.org/10.1111/j.1469-7793.1999.0611v.x
503	47.	Fung, M. M., Peters, K., Redline, S., Ziegler, M. G., Ancoli-Israel, S., Barrett-
504	.,.	Connor, E., Stone, K. L., & Osteoporotic Fractures in Men Research Group.
505		Decreased slow wave sleep increases risk of developing hypertension in elderly
506		men. <i>Hypertension</i> 2011;58(4): 596–603.
507		https://doi.org/10.1161/HYPERTENSIONAHA.111.174409
508	48	Gottlieb, D. J., Yenokyan, G., Newman, A. B., O'Connor, G. T., Punjabi, N.
509	40.	M., Quan, S. F., Redline, S., Resnick, H. E., Tong, E. K., Diener-West, M., &
510		Shahar, E. Prospective study of obstructive sleep apnea and incident coronary
511		heart disease and heart failure: the sleep heart health study. <i>Circulation</i>
512		2010;122(4):352-60.
512		
	40	https://doi.org/10.1161/CIRCULATIONAHA.109.901801
514	49.	Gulia, K. K., & Kumar, V. M. Sleep disorders in the elderly: a growing
515		challenge. <i>Psychogeriatrics</i> 2018;18(3): 155–65.
516	50	https://doi.org/10.1111/psyg.12319
517	50.	Lindam, A., Jansson, C., Nordenstedt, H., Pedersen, N. L., & Lagergren, J. A
518		population-based study of gastroesophageal reflux disease and sleep problems
519		in elderly twins. <i>PloS One</i> 2012;7(10): e48602.
520	<b>_</b> .	https://doi.org/10.1371/journal.pone.0048602
521	51.	Moraes, W., Piovezan, R., Poyares, D., Bittencourt, L. R., Santos-Silva, R., &
522		Tufik, S. Effects of aging on sleep structure throughout adulthood: a

523		population-based study. Sleep Med 2014;15(4): 401–9.
524		https://doi.org/10.1016/j.sleep.2013.11.791
525	52.	Medicine, A. A. o. S. Insomnia. in: International Classification of Sleep
526		Disorders (M. Sateia, Ed.). American Association of Sleep Medicine 2014.
527	53.	Chung, S., Cho, S. W., Jo, M. W., Youn, S., Lee, J., & Sim, C. S. The
528		Prevalence and Incidence of Insomnia in Korea during 2005 to 2013.
529		Psychiatry Investig 2020;17(6): 533-40. https://doi.org/10.30773/pi.2019.0218
530	54.	Son, C., Lim, Y., Lee, Y. et al. Analysis of Medical Services for Insomnia in
531		Korea: A Retrospective, Cross-Sectional Study Using the Health Insurance
532		Review and Assessment Claims Data. <i>Healthcare</i> 2022;10(1): 7.
533		https://doi.org/10.3390/healthcare10010007
534	55.	Hillman, D., Mitchell, S., Streatfeild, J., Burns, C., Bruck, D., & Pezzullo, L.
535		The economic cost of inadequate sleep. <i>Sleep</i> 2018;41(8): 7.
536		10.1093/sleep/zsy083. https://doi.org/10.1093/sleep/zsy083
537	56.	Walsh, J. K., & Engelhardt, C. L. The direct economic costs of insomnia in the
538		United States for 1995. Sleep 1999;22: S386–S393.
539	57.	Wickwire, E. M., Shaya, F. T., & Scharf, S. M. Health economics of insomnia
540		treatments: The return on investment for a good night's sleep. Sleep Med Rev
541		2016;30: 72-82. https://doi.org/10.1016/j.smrv.2015.11.004
542	58.	Seockhoon Chung, S. K., T Kim, et al. Korean version of insomnia clinical
543		practice guideline: Diagnosis and treatment of insomnia. Korean
544		NeuroPsychiatric Association 2019.

	Total	Men	Women
$N^*$	7,467,730	3,015,102 (40.3%)	4,452,628 (59.62%)
Age	$53.5\pm18.0$	$52.3 \pm 18.2$	$54.3 \pm 17.7$
Age group			
≤10	73,056 (1.0%)	41,865 (1.4%)	31,191 (0.7%)
10<, 20	199,552 (2.7%)	95,179 (3.2%)	104,373 (2.3%)
20<, 30	630,869 (8.4%)	268,313 (8.9%)	362,556 (8.1%)
30<, 40	885,756 (11.9%)	389,187 (12.9%)	496,569 (11.2%)
40<, 50	1,288,480 (17.3%)	526,319 (17.5%)	762,161 (17.1%)
50<, 60	1,644,936 (22.0%)	626,554 (20.8%)	1,018,382 (22.9%)
60<, 70	1,319,966 (17.7%)	533,208 (17.7%)	786,758 (17.7%)
70<	1,425,115 (19.1%)	534,477 (17.7%)	890,638 (20.0%)

# 545 Table 1. Basic characteristics of study population

546 Data are represented as number and proportion (%) or mean ± standard deviation.

547 \* Proportion was calculated using rows.

Table 2. Use of medical services by sex

Variables	Total	Male	Female	p-value
Total number of medical visits	86,242,369	32,983,344	53,259,025	
Number of medical visits per patient	11.5 (± 26.6)	10.9 (± 25.4)	11.7 (± 27.4)	< 0.0001
Type of medical service				
Korean medicine	8,323,747 (9.7%)	2,257,536 (6.8%)	6,066,211 (11.4%)	-0.0001
Western medicine	77,918,622 (90.3%)	30,725,808 (93.2%)	47,192,814 (88.6%)	< 0.0001
Type of medical visit				
Inpatient admission	2,488,588 (2.9%)	1,478,311 (4.5%)	1,010,277 (1.9%)	<0.0001
Outpatient visit	83,753,781 (97.1%)	31,505,033 (95.5%)	52,248,748 (98.1%)	<0.0001
Medical expenses per visit				
Total medical expenses	71,931 (± 372,377)	91,654 (± 453,808)	59,716 (± 310,819)	< 0.0001
Patient charge	12,785 (± 56,287)	14,697 (± 63,616)	11,601 (± 51,188)	< 0.0001
Drug prescription fee	11,629 (± 161,062)	12,651 (± 244,311)	10,996 (± 71,006)	< 0.0001
Medical expenses per patient				
Total medical expenses	830,707 (± 4,595,063)	$1,002,640 (\pm 5,476,533)$	714,282 (± 3,881,934)	< 0.0001
Patient charge	147,655 (714,887)	160,782 (± 792,815)	138,765 (± 138,765)	< 0.0001
Medication prescription fee	134,300 (± 929,518)	138,394 (± 1,107,515)	131,528 (± 786,423)	< 0.0001

Data are represented as number and proportion (%) or mean  $\pm$  standard deviation.

# **Figure legends**

Figure 1. Distribution by type of sleep disorder according to ICSD-3 classification

Figure 2. Annual prevalence of sleep disorders for ten years by sex (2011–2020)

Figure 3. Annual use of medical services for sleep disorders by sex (2011–2020)

Figure 4. Medication prescriptions for sleep disorders by medical type

Supplementary figure 1. Treatment prescriptions of Korean medicine, excluding herbal medicine




Figure 1. Distribution by type of sleep disorder according to ICSD-3 classification




Figure 2. Annual prevalence of sleep disorders for ten years by sex (2011–2020)




Figure 3. Annual use of medical services for sleep disorders by sex (2011–2020)




Figure 4. Medication prescriptions for sleep disorders by medical type